Hennion & Walsh Asset Management, Inc. Lexicon Pharmaceuticals, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.06 Billion
- Q3 2024
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 731,138 shares of LXRX stock, worth $891,988. This represents 0.06% of its overall portfolio holdings.
Number of Shares
731,138
Previous 542,899
34.67%
Holding current value
$891,988
Previous $912,000
25.77%
% of portfolio
0.06%
Previous 0.05%
Shares
2 transactions
Others Institutions Holding LXRX
# of Institutions
129Shares Held
240MCall Options Held
617KPut Options Held
286K-
Artal Group S.A. Luxembourg, N4175MShares$214 Million18.64% of portfolio
-
Black Rock Inc. New York, NY9.89MShares$12.1 Million0.0% of portfolio
-
Braidwell LP Stamford, CT8.29MShares$10.1 Million0.44% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.68MShares$9.36 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.85MShares$7.13 Million0.24% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $230M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...